Lotus Clinical Research Announces the Addition of Robert Dworkin, PhD as Director, Chronic Pain Research
Robert Dworkin, Ph.D. Joins Lotus Clinical Research as Director, Chronic Pain Research to lead Lotus' chronic pain research programs
PASADENA, Calif., January 15, 2019 (Newswire.com) - Lotus Clinical Research, a specialty analgesic full-service CRO, has announced the addition of Robert (Bob) Dworkin, Ph.D. as Director of Chronic Pain Research. In his new role, Dr. Dworkin will lead Lotus’ current chronic pain research programs and work to expand Lotus’ chronic pain expertise and capabilities.
“Lotus Clinical Research is the leading CRO for acute pain analgesic clinical trials. I am very enthusiastic to be collaborating with their strong, experienced, analgesic CRO team as they grow their chronic pain base and increase the number of chronic pain clinical trials,” said Dworkin. “I strongly endorse the Lotus mission to develop and validate innovative methods to improve the scientific accuracy of analgesic clinical trials and thereby accelerate the development of treatments with improved efficacy and safety. These efforts have great potential to reduce prescription drug abuse and help combat the opioid crisis, and I appreciate their focus on designing and conducting scientifically rigorous analgesic trials.”
Robert H. Dworkin, Ph.D., received his BA from the University of Pennsylvania and his Ph.D. from Harvard University and has served as a consultant to over 160 pharmaceutical and device companies in the development and evaluation of analgesic and antiviral treatments. He has been the principal investigator for a large number of clinical trials funded by government and industry, which have examined treatments for various types of chronic pain, including painful diabetic peripheral neuropathy, low back pain, osteoarthritis, cancer pain, fibromyalgia, and postherpetic neuralgia, as well as treatments for acute post-surgical pain and shingles pain.
Dr. Dworkin has spent over 35 years conducting clinical research on acute and chronic pain. In addition to his position at Lotus, he is currently Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, Professor in the Center for Health + Technology, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry; Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration (FDA); Special Government Employee of the FDA Center for Drug Evaluation and Research; and Associate Editor of Pain and a member of the Editorial Boards of Canadian Journal of Pain and Journal of Pain.
The primary focus of Dr. Dworkin’s current research involves the identification of factors that increase the assay sensitivity of clinical trials to detect differences between an active and a placebo control or comparison treatment. In ongoing studies, he and his colleagues are examining the relationships between clinical trial results and their research designs, patient characteristics, statistical methods, and outcome measures. Dr. Dworkin has also been very interested in the identification of risk factors for the transition from acute to chronic pain. In joining Lotus Clinical Research, Dr. Dworkin is responsible for leading chronic pain development efforts and assisting with further building our CRO infrastructure to further expand our resources and drive anticipated growth.
“Lotus Clinical Research is steadily expanding its capabilities and scope by building a world-class analgesic leadership team, committed to meeting our clients’ and society’s needs,” said Lotus CEO, Neil Singla, MD. “With Dr. Dworkin and other key leaders in place, we’re well equipped to deliver truly comprehensive analgesic clinical trial services in both acute and chronic pain.”
“Dr. Dworkin is perhaps the world’s leading expert in chronic pain clinical trials, and as the driving force behind the ACTTION public-private partnership, he has significantly advanced the field of analgesic research globally,” said Dr. Singla. “Dr. Dworkin and I have collaborated for many years in research supported by ACTTION and in advising shared pharmaceutical clients on their pain programs. His new position with Lotus adds significant depth to our scientific team and bolsters Lotus’ ability to lead the CRO space in chronic pain study design and conduct.”
About Lotus Clinical Research: Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments and has played a role in 10 analgesic FDA approvals. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain providing scientific leadership at every step of the development process. In assisting with the advancement of pain therapies, Lotus Clinical Research seeks to invent and operationalize research methods that improve study design and conduct for analgesic trials, which support our mission to help alleviate the opioid crisis in society.
Source: Lotus Clinical Research